Cabergoline

Cabergoline, often called caber or Dostinex, is an oral medicine that lowers prolactin. People discuss it for high-prolactin symptoms, libido and sexual function, and alongside nandrolone or trenbolone. Reports include restored desire, no improvement and feeling worse; a sexual symptom alone does not identify its cause.

A long-acting dopamine agonist. It activates dopamine D2 receptors involved in prolactin release. Prolactin is a hormone associated with lactation; excess levels can disrupt reproductive function. Caber is an ergot-derived drug, not a peptide, testosterone replacement, estrogen blocker or erection medicine. Dostinex Profile (Secondhand community claim · Accessed 2026-09-30)

Relief of nipple discharge or presumed 19-nor sides. Bodybuilding discussions connect caber with nandrolone and trenbolone, sometimes calling the problem prolactin gyno or Deca dick. The original record includes reported relief and disagreement: estrogen, other drugs, sleep and progestin effects can complicate that explanation.

Source context — Dostinex Profile: Formal material reposted in a bodybuilding forum, not community-generated human measurements. Original linked study not independently opened; animal target-organ persistence does not establish human elimination.

More desire, easier erections or orgasm. A testosterone replacement therapy (TRT) forum user reported improved sensitivity, libido and orgasms. High-prolactin patients describe returning morning erections and energy, but another reports no libido improvement after five months despite lower prolactin. These are different starting problems, not interchangeable outcomes. cabergoline (Personal report · Accessed 2026-09-30) · My libido is non existent!! (Community discussion · Accessed 2026-09-30)

Unwanted effects may start before benefits. An oral 0.25 mg twice-weekly patient reports headaches and nausea within 24 hours. Another report describes sexual function worsening in the first week while prolactin fell. Neither establishes a universal adjustment period. Cabergoline Side Effects (Community discussion · Accessed 2026-09-30) · My prolactin level became zero after two weeks of taking Cabergoline (Personal report · Accessed 2026-09-30)

Lower prolactin is not always a better experience. A TRT user reported prolactin below the lab range with worse sexual performance. Original reports also mention flat mood, anhedonia and dry eyes; these symptoms do not prove over-suppression. Bloodwork and the wider hormone picture matter more than guessing from libido alone. Blood Work Friday: 2022-10-28 (Community discussion · Accessed 2026-09-30)

Hours for some feelings; weeks or months for sexual recovery. One patient describes extra energy and assertiveness a few hours after a dose. Others report libido returning after 2–3 weeks or a couple of months. The original AAS discussions judge symptoms over 2–8 weeks. These are different endpoints, not one dependable onset range. My libido is non existent!! (Community discussion · Accessed 2026-09-30)

More libido can become uncomfortable. A returning-libido patient describes desire becoming almost excessive. Another reports overstimulation and 24 hours without sleep after a dose increase. Feeling more driven is not automatically the same as restored wellbeing. My libido is non existent!! (Community discussion · Accessed 2026-09-30) · Who has experienced Cabergoline side effects? (Community discussion · Accessed 2026-09-30)

Source context — cabergoline: TRT-related sexual concern; no measured onset, prolactin baseline or long-term outcome. Selegiline is a proposed combination, not an experienced combination; alternatives in replies are opinions.

Source context — My libido is non existent!!: Patient self-reports, not AAS outcomes; OP also starts testosterone and another respondent mentions clomid. No laboratory records authenticated. Five-month nonresponse is one report, not a rate.

Source context — Cabergoline Side Effects: EDS, migraines, stress and disease itself confound symptoms; later follow-up has relative timestamp only. No universal adaptation period or self-directed route-switch claim accepted. This reopens the exact source in frozen detail rather than fabricating a replacement.

Source context — My prolactin level became zero after two weeks of taking Cabergoline: Self-reported zero result and normal starting level; units omitted, tumor and endocrine interpretation unverified. A reply's 250mg typo is not converted into an accepted dose. Replies' stop/switch advice not adopted.

Source context — Blood Work Friday: 2022-10-28: TRT, self-reported labs and timing; follow-up clarifies results were four weeks after stopping. Oral route follows tablet context and original record, not an independently confirmed product. Clinical postpartum data quoted by a commenter are not counted as a community human duration measurement.

Source context — Who has experienced Cabergoline side effects?: Self-selected patient thread, unverified diagnoses and doses; some replies omit tablet strength. No side-effect prevalence estimate or advice to push through fainting inferred.

0.25 mg per administration, twice weekly: 0.5 mg total per week. This appears in bodybuilding plans, TRT reports and the original community record. It also mirrors a clinical starting schedule; a familiar number does not establish that someone's prolactin needs lowering. Blood Work Friday: 2022-10-28 (Community discussion · Accessed 2026-09-30) · Questions about Prolactin and Progesterone on first tren cycle (Community discussion · Accessed 2026-09-30)

0.5 mg twice weekly: 1 mg total weekly in one TRT account. That user's positive report does not establish a dose-response rule. The original record also repeats 1 mg twice weekly as a supposed ceiling; this comes from clinical labeling, not a community safety measurement. cabergoline (Personal report · Accessed 2026-09-30)

Lower weekly totals and more frequent variants also appear. Original discussions include 0.25–0.5 mg total weekly, sometimes divided, and 0.25 mg every third day. They are separate patterns. The latter is a per-dose amount, not a weekly total.

Tablet amounts are milligrams. The usual discussed form is a scored 0.5 mg oral tablet. Original accounts describe halves as 0.25 mg and quarters as approximately 0.125 mg, with uneven splitting a concern. These are descriptions, not a pill-splitting routine.

Clinical dosing and lactation uses have separate rules. The US starting schedule is 0.25 mg twice weekly, with changes at least four weeks apart and a maximum of 1 mg twice weekly. US information advises avoiding postpartum lactation suppression; UK labeling includes that indication. Neither supplies a bodybuilding regimen. US cabergoline prescribing information (Official context · Accessed 2026-09-30) · Dostinex Tablets SmPC (Official context · Accessed 2026-09-30)

Source context — Blood Work Friday: 2022-10-28: TRT, self-reported labs and timing; follow-up clarifies results were four weeks after stopping. Oral route follows tablet context and original record, not an independently confirmed product. Clinical postpartum data quoted by a commenter are not counted as a community human duration measurement.

Source context — Questions about Prolactin and Progesterone on first tren cycle: Plan and opinions, not successful treatment log. Commercial affiliations and seller links in signatures/replies; no sourcing reproduced. Broad claims about all tren users, supplements providing protection or recreational safety rejected.

Source context — cabergoline: TRT-related sexual concern; no measured onset, prolactin baseline or long-term outcome. Selegiline is a proposed combination, not an experienced combination; alternatives in replies are opinions.

Source context — US cabergoline prescribing information: Disease-label context, not a bodybuilding protocol or measured libido timing. US lactation position differs from UK. No clinical dose is converted into a community safety limit.

Source context — Dostinex Tablets SmPC: Regional product summary; differences in populations and assays are not averaged. Rat pituitary radioactivity is identified as animal context, not parent-drug human half-life. Formal results remain outside quick answers.

Hours for some feelings; weeks or months for sexual recovery. One patient describes extra energy and assertiveness a few hours after a dose. Others report libido returning after 2–3 weeks or a couple of months. The original AAS discussions judge symptoms over 2–8 weeks. These are different endpoints, not one dependable onset range. My libido is non existent!! (Community discussion · Accessed 2026-09-30)

Unwanted effects may start before benefits. An oral 0.25 mg twice-weekly patient reports headaches and nausea within 24 hours. Another report describes sexual function worsening in the first week while prolactin fell. Neither establishes a universal adjustment period. Cabergoline Side Effects (Community discussion · Accessed 2026-09-30) · My prolactin level became zero after two weeks of taking Cabergoline (Personal report · Accessed 2026-09-30)

More desire, easier erections or orgasm. A testosterone replacement therapy (TRT) forum user reported improved sensitivity, libido and orgasms. High-prolactin patients describe returning morning erections and energy, but another reports no libido improvement after five months despite lower prolactin. These are different starting problems, not interchangeable outcomes. cabergoline (Personal report · Accessed 2026-09-30) · My libido is non existent!! (Community discussion · Accessed 2026-09-30)

No reliable single-dose libido window. One bodybuilding poster claims prolactin lowering lasts 4–5 days, without showing measurements. A TRT user still reported low prolactin four weeks after stopping a three-week course. Repeated-use carryover and hormone recovery cannot be read as one-dose benefit duration. Test tren cycle (Community discussion · Accessed 2026-09-30) · Blood Work Friday: 2022-10-28 (Community discussion · Accessed 2026-09-30)

Side effects can last beyond the dosing night. One patient reports 2–3 days of symptoms after a dose; another still had intermittent nausea and dizziness a month after stopping. Those are adverse experiences with uncertain causes, not drug-clearance measurements. Cabergoline Side Effects (Community discussion · Accessed 2026-09-30) · Who has experienced Cabergoline side effects? (Community discussion · Accessed 2026-09-30)

Official measurements have specific populations and endpoints. US information reports 63–69 hours elimination in healthy subjects and a 2–3-hour plasma peak. UK information gives 63–68 hours in healthy volunteers and 79–115 hours in hyperprolactinemic patients, using different assays. It reports prolactin reduction within three hours lasting 7–28 days in some studied groups; rat pituitary radioactivity is a separate observation. US cabergoline prescribing information (Official context · Accessed 2026-09-30) · Dostinex Tablets SmPC (Official context · Accessed 2026-09-30)

About 65 hours or three days is repeated in forums. These are secondhand pharmacokinetic claims, not measurements by users. An older forum profile explicitly reproduces label-style healthy-volunteer and patient estimates. Half-life describes drug elimination; it cannot predict libido recovery or a symptom-free day. Blood Work Friday: 2022-10-28 (Community discussion · Accessed 2026-09-30) · Pill days (Secondhand community claim · Accessed 2026-09-30) · Dostinex Profile (Secondhand community claim · Accessed 2026-09-30)

Source context — My libido is non existent!!: Patient self-reports, not AAS outcomes; OP also starts testosterone and another respondent mentions clomid. No laboratory records authenticated. Five-month nonresponse is one report, not a rate.

Source context — Cabergoline Side Effects: EDS, migraines, stress and disease itself confound symptoms; later follow-up has relative timestamp only. No universal adaptation period or self-directed route-switch claim accepted. This reopens the exact source in frozen detail rather than fabricating a replacement.

Source context — My prolactin level became zero after two weeks of taking Cabergoline: Self-reported zero result and normal starting level; units omitted, tumor and endocrine interpretation unverified. A reply's 250mg typo is not converted into an accepted dose. Replies' stop/switch advice not adopted.

Source context — cabergoline: TRT-related sexual concern; no measured onset, prolactin baseline or long-term outcome. Selegiline is a proposed combination, not an experienced combination; alternatives in replies are opinions.

Source context — Test tren cycle: Several overlapping drugs, inconsistent schedule mentions and no posted prolactin measurement supporting the 4–5-day claim. Duplicate posts 29–31 and quoted repeats counted once. The lifetime cardiac-safety assurance is rejected. Tren unit typo not reproduced.

Source context — Blood Work Friday: 2022-10-28: TRT, self-reported labs and timing; follow-up clarifies results were four weeks after stopping. Oral route follows tablet context and original record, not an independently confirmed product. Clinical postpartum data quoted by a commenter are not counted as a community human duration measurement.

Source context — Who has experienced Cabergoline side effects?: Self-selected patient thread, unverified diagnoses and doses; some replies omit tablet strength. No side-effect prevalence estimate or advice to push through fainting inferred.

Source context — US cabergoline prescribing information: Disease-label context, not a bodybuilding protocol or measured libido timing. US lactation position differs from UK. No clinical dose is converted into a community safety limit.

Source context — Dostinex Tablets SmPC: Regional product summary; differences in populations and assays are not averaged. Rat pituitary radioactivity is identified as animal context, not parent-drug human half-life. Formal results remain outside quick answers.

Source context — Pill days: No pharmacokinetic study supplied by poster. Half-life repeated as a scheduling explanation is not a measured personal clearance result or dosing instruction.

Source context — Dostinex Profile: Formal material reposted in a bodybuilding forum, not community-generated human measurements. Original linked study not independently opened; animal target-organ persistence does not establish human elimination.

Whole-cycle prevention versus using it only when a problem emerges. Both positions remain in the original AAS record. An inspected tren thread starts with planned twice-weekly caber despite already-low prolactin; the poster then changes toward monitoring. That debate supplies no established cabergoline cycle length or scheduled break. Questions about Prolactin and Progesterone on first tren cycle (Community discussion · Accessed 2026-09-30)

Stop timing differs between bodybuilding and disease treatment. Original AAS accounts stop when sides settle or the associated drug clears, and revisit caber on later runs. Patient discussions include years of supervised use. Neither establishes a universal taper, washout or safe repeat-course rule. Cabergoline Side Effects (Community discussion · Accessed 2026-09-30)

Source context — Questions about Prolactin and Progesterone on first tren cycle: Plan and opinions, not successful treatment log. Commercial affiliations and seller links in signatures/replies; no sourcing reproduced. Broad claims about all tren users, supplements providing protection or recreational safety rejected.

Source context — Cabergoline Side Effects: EDS, migraines, stress and disease itself confound symptoms; later follow-up has relative timestamp only. No universal adaptation period or self-directed route-switch claim accepted. This reopens the exact source in frozen detail rather than fabricating a replacement.

19-nor AAS adjacency: Most-discussed pairing is with nandrolone (Deca/NPP) or trenbolone when users attribute lactation-type sides, sexual dysfunction, or “prolactin gyno” to those compounds. Caber is treated as a side-management tool, not an anabolic. [community]

Relief of nipple discharge or presumed 19-nor sides. Bodybuilding discussions connect caber with nandrolone and trenbolone, sometimes calling the problem prolactin gyno or Deca dick. The original record includes reported relief and disagreement: estrogen, other drugs, sleep and progestin effects can complicate that explanation.

Adding drugs can obscure which problem changed. Original stacks include estrogen blockers, tadalafil or sildenafil, PT-141 and P5P (active vitamin B6). Pramipexole and bromocriptine are compared for tolerance and dosing convenience, not treated as equivalent substitutes. A tren log describes guessing at gyno treatment before abdominal pain, swelling and tingling appeared amid several drugs. Test tren cycle (Community discussion · Accessed 2026-09-30)

P5P / vitamin B6 discussion: Pyridoxal-5-phosphate and higher-dose B6 appear as proposed alternatives or additions for prolactin. Calling them milder does not establish comparative safety, equivalent potency or a supported combination. [community]

PDE5 combo: Occasional logs stack tadalafil/sildenafil for erection quality while using caber for presumed prolactin — separate mechanisms; hard to attribute which agent helped. [anecdote]

PT-141 / other libido agents: Mentioned in sexual-function stacks; dopaminergic + melanocortin combinations are experimental in user logs, not standard endocrine care. [anecdote]

Not an AI substitute: Estrogen control (anastrozole, exemestane, etc.) is a separate axis problem from prolactin. Forums repeatedly warn against using caber to “fix gyno” that is actually high-E2. [community]

Estrogen blockers with cabergoline: Some logs combine an AI for presumed E2 problems with cabergoline for presumed prolactin problems. Symptoms and a copied laboratory schedule do not establish either diagnosis or combination safety. [community]

Source context — Test tren cycle: Several overlapping drugs, inconsistent schedule mentions and no posted prolactin measurement supporting the 4–5-day claim. Duplicate posts 29–31 and quoted repeats counted once. The lifetime cardiac-safety assurance is rejected. Tren unit typo not reproduced.

Lower prolactin is not always a better experience. A TRT user reported prolactin below the lab range with worse sexual performance. Original reports also mention flat mood, anhedonia and dry eyes; these symptoms do not prove over-suppression. Bloodwork and the wider hormone picture matter more than guessing from libido alone. Blood Work Friday: 2022-10-28 (Community discussion · Accessed 2026-09-30)

Serious physical or behavioral changes need medical attention. Official warnings include fainting from standing blood-pressure drops, compulsive sexual or gambling urges, and valve or fibrotic disease. Heart evaluation and echocardiographic monitoring are specified. Small weekly doses do not erase these concerns; chest pain, breathlessness or swelling warrant assessment. US cabergoline prescribing information (Official context · Accessed 2026-09-30)

Interactions and product identity change the picture. Dopamine-blocking medicines can oppose caber. UK information flags macrolide antibiotics and other blood-pressure-lowering drugs. Original community notes question counterfeit or unevenly potent tablets; packaging and a forum review cannot verify contents. US cabergoline prescribing information (Official context · Accessed 2026-09-30) · Dostinex Tablets SmPC (Official context · Accessed 2026-09-30)

Tablet amounts are milligrams. The usual discussed form is a scored 0.5 mg oral tablet. Original accounts describe halves as 0.25 mg and quarters as approximately 0.125 mg, with uneven splitting a concern. These are descriptions, not a pill-splitting routine.

Source context — Blood Work Friday: 2022-10-28: TRT, self-reported labs and timing; follow-up clarifies results were four weeks after stopping. Oral route follows tablet context and original record, not an independently confirmed product. Clinical postpartum data quoted by a commenter are not counted as a community human duration measurement.

Source context — US cabergoline prescribing information: Disease-label context, not a bodybuilding protocol or measured libido timing. US lactation position differs from UK. No clinical dose is converted into a community safety limit.

Source context — Dostinex Tablets SmPC: Regional product summary; differences in populations and assays are not averaged. Rat pituitary radioactivity is identified as animal context, not parent-drug human half-life. Formal results remain outside quick answers.